<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881334</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00045700</org_study_id>
    <nct_id>NCT01881334</nct_id>
  </id_info>
  <brief_title>Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants</brief_title>
  <official_title>A Compassionate Release Protocol: Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Allogeneic Transplantation Using a Related Haplo-Identical Donor and Unrelated, Umbilical Cord Blood Donor(s) for the Treatment of High Risk Malignancies or Non-Malignant Disorders Requiring Allogeneic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joanne Kurtzberg, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Miltenyi Biotec, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      The objective of this study is to make T-cell depleted stem cells from a family member who is&#xD;
      a half match (haplo-identical) available on an expanded access basis to patients receiving&#xD;
      one or two unrelated cord blood transplants who are at a higher risk of not engrafting in a&#xD;
      safe amount of time. The purpose of the related stem cells is the give the bone marrow a&#xD;
      &quot;jump start&quot; towards recovery. Ultimately, the cord blood cells will grow and permanently&#xD;
      rescue the bone marrow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of the study is to provide expanded access of T-cell depleted&#xD;
      haplo-identical stem cells for patients receiving allogeneic transplantation from a related&#xD;
      haplo-identical donor and an unrelated, umbilical cord blood (UUCB) unit(s) for the treatment&#xD;
      of high risk malignancies and non-malignant disorders. The T-cell depleted haplo-identical&#xD;
      stems cells are intended to facilitate early, short-term myeloid engraftment with the primary&#xD;
      goal of minimizing early infections and other non-relapse mortality while the UUCB cells&#xD;
      engraft as the durable and permanent graft. Patients with high risk or refractory&#xD;
      malignancies, or non-malignant disorders amenable to stem cell transplantation therapy but&#xD;
      lacking conventional related or unrelated donors will be eligible for this protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Hematologic Malignancies</condition>
  <condition>Inborn Errors of Metabolism Disorders</condition>
  <condition>Immune Deficiencies</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CliniMACS CD34 Reagent System</intervention_name>
    <description>The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a consenting related haplo-identical (3/6, 4/6, or 5/6 if DRB1 mismatch) stem&#xD;
             cell donor.&#xD;
&#xD;
          -  Have one or two available 4, 5, or 6/6 antigen matching unrelated UCB unit(s) that&#xD;
             will deliver a total cell dose &gt;3.0 x 10e7 cells/kg. Patients who do not have a single&#xD;
             UCB unit that will deliver the minimum required cell dose, two partially HLA-matched&#xD;
             UCB units which together meet the minimum cell dose requirement, can be used for 1&#xD;
             transplant. These units must be HLA-matched minimally at 4 of 6 HLA-A and B (at&#xD;
             intermediate resolution by molecular typing) and DRB1 (at high resolution by molecular&#xD;
             typing) loci with the patient, and HLA-matched at 3 of 6 HLA- A, B, DRB1 loci with&#xD;
             each other (using same resolution of HLA typing as indicated above). There is no&#xD;
             limitation on maximum cell dose.&#xD;
&#xD;
          -  Have a high risk or refractory malignancy, or non-malignant disorder amenable to stem&#xD;
             cell transplantation therapy.&#xD;
&#xD;
          -  Meet eligibility requirements for allogeneic transplant per institutional standard&#xD;
             practices.&#xD;
&#xD;
          -  Have given written informed consent according to FDA guidelines (or consent of&#xD;
             parent/legal guardian as applicable).&#xD;
&#xD;
          -  Be &lt;65 years of age at the time of study enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a consenting 8/8 or 10/10 allele matched, consenting, related or unrelated&#xD;
             hematopoietic stem cell transplant (HSCT) donor.&#xD;
&#xD;
          -  Have a life expectancy of less than 3 months.&#xD;
&#xD;
          -  Have uncontrolled infections at time of cytoreduction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Joanne Kurtzberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin D Arbuckle</last_name>
    <phone>919-684-3293</phone>
    <email>erin.arbuckle@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Erin Arbuckle</last_name>
      <email>erin.arbuckle@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Joanne Kurtzberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Joanne Kurtzberg, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Haploidentical Donor</keyword>
  <keyword>T-cell depleted Stem Cells</keyword>
  <keyword>Allogeneic Transplant</keyword>
  <keyword>Umbilical Cord Blood Donor</keyword>
  <keyword>High Risk Malignancies</keyword>
  <keyword>Metabolic Disorders</keyword>
  <keyword>Immune Deficiency</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>CGD</keyword>
  <keyword>SCID</keyword>
  <keyword>Adrenoleukodystrophy</keyword>
  <keyword>Metachromaticleukodystrophy</keyword>
  <keyword>Krabbe</keyword>
  <keyword>PMD</keyword>
  <keyword>Hunter's</keyword>
  <keyword>Hurler's</keyword>
  <keyword>Severe Aplastic Anemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Thalassemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

